JPI 547Alternative Names: JPI-547
Latest Information Update: 17 Mar 2016
$50 / €47 *
At a glance
- Originator Jeil Pharmaceutical
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors; Tankyrase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Colorectal cancer
Most Recent Events
- 17 Mar 2016 JPI 547 is available for licensing as of 17 Mar 2016 (Jeil Pharmaceutical's website, March 2016).
- 17 Mar 2016 Preclinical trials in Colorectal cancer in South Korea (unspecified route) prior to March 2016 (Jeil Pharmaceutical's pipeline, March 2016)